nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—osteoarthritis—Prednisone—psoriasis	0.404	1	CpDpCtD
Meloxicam—PGD—Methotrexate—psoriasis	0.087	0.206	CbGbCtD
Meloxicam—CYP2C8—Tazarotene—psoriasis	0.0463	0.11	CbGbCtD
Meloxicam—PTGS2—Triamcinolone—psoriasis	0.0352	0.0832	CbGbCtD
Meloxicam—PTGS2—Betamethasone—psoriasis	0.0302	0.0714	CbGbCtD
Meloxicam—ABCC4—Methotrexate—psoriasis	0.024	0.0568	CbGbCtD
Meloxicam—CYP2C8—Cholecalciferol—psoriasis	0.0198	0.0468	CbGbCtD
Meloxicam—PTGS2—Dexamethasone—psoriasis	0.0176	0.0415	CbGbCtD
Meloxicam—CYP2C8—Mycophenolate mofetil—psoriasis	0.0171	0.0406	CbGbCtD
Meloxicam—CYP3A4—Calcitriol—psoriasis	0.0156	0.0368	CbGbCtD
Meloxicam—CYP2C9—Cholecalciferol—psoriasis	0.0138	0.0326	CbGbCtD
Meloxicam—CYP2C8—Hydrocortisone—psoriasis	0.0138	0.0326	CbGbCtD
Meloxicam—CYP2C8—Cyclosporine—psoriasis	0.013	0.0307	CbGbCtD
Meloxicam—CYP3A4—Methoxsalen—psoriasis	0.0121	0.0286	CbGbCtD
Meloxicam—CYP2C9—Cyclosporine—psoriasis	0.00906	0.0214	CbGbCtD
Meloxicam—CYP2C8—Dexamethasone—psoriasis	0.00856	0.0202	CbGbCtD
Meloxicam—CYP3A4—Cholecalciferol—psoriasis	0.00802	0.019	CbGbCtD
Meloxicam—CYP3A4—Triamcinolone—psoriasis	0.00695	0.0165	CbGbCtD
Meloxicam—CYP3A4—Mycophenolate mofetil—psoriasis	0.00695	0.0165	CbGbCtD
Meloxicam—CYP2C9—Dexamethasone—psoriasis	0.00597	0.0141	CbGbCtD
Meloxicam—CYP3A4—Betamethasone—psoriasis	0.00596	0.0141	CbGbCtD
Meloxicam—CYP3A4—Prednisolone—psoriasis	0.00589	0.0139	CbGbCtD
Meloxicam—CYP3A4—Hydrocortisone—psoriasis	0.00558	0.0132	CbGbCtD
Meloxicam—CYP3A4—Prednisone—psoriasis	0.00556	0.0132	CbGbCtD
Meloxicam—CYP3A4—Cyclosporine—psoriasis	0.00527	0.0125	CbGbCtD
Meloxicam—CYP3A4—Dexamethasone—psoriasis	0.00347	0.00821	CbGbCtD
Meloxicam—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000547	0.157	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000438	0.126	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000425	0.122	CbGdCrCtD
Meloxicam—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000392	0.0768	CbGpPWpGaD
Meloxicam—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.00033	0.0948	CbGdCrCtD
Meloxicam—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000319	0.0625	CbGpPWpGaD
Meloxicam—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000264	0.076	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000264	0.076	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000257	0.0738	CbGdCrCtD
Meloxicam—PTGS2—skeletal joint—psoriasis	0.000255	0.228	CbGeAlD
Meloxicam—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000243	0.0476	CbGpPWpGaD
Meloxicam—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.0002	0.0574	CbGdCrCtD
Meloxicam—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.0002	0.0574	CbGdCrCtD
Meloxicam—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000198	0.0388	CbGpPWpGaD
Meloxicam—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000195	0.0561	CbGdCrCtD
Meloxicam—PTGS2—synovial membrane of synovial joint—psoriasis	0.000194	0.173	CbGeAlD
Meloxicam—ABCC4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000177	0.0348	CbGpPWpGaD
Meloxicam—PGD—NRF2 pathway—TGFA—psoriasis	0.000133	0.0262	CbGpPWpGaD
Meloxicam—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00013	0.0256	CbGpPWpGaD
Meloxicam—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000127	0.0248	CbGpPWpGaD
Meloxicam—PTGS2—skin epidermis—psoriasis	0.000124	0.111	CbGeAlD
Meloxicam—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.00012	0.0346	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.00012	0.0346	CbGdCrCtD
Meloxicam—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000118	0.0338	CbGdCrCtD
Meloxicam—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000101	0.0198	CbGpPWpGaD
Meloxicam—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.95e-05	0.0195	CbGpPWpGaD
Meloxicam—PGD—skin of body—psoriasis	9.62e-05	0.086	CbGeAlD
Meloxicam—PTGS1—endothelium—psoriasis	9.43e-05	0.0844	CbGeAlD
Meloxicam—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	9.34e-05	0.0183	CbGpPWpGaD
Meloxicam—PTGS2—endothelium—psoriasis	9.02e-05	0.0807	CbGeAlD
Meloxicam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.21e-05	0.0161	CbGpPWpGaD
Meloxicam—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.17e-05	0.016	CbGpPWpGaD
Meloxicam—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.1e-05	0.0159	CbGpPWpGaD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	7.76e-05	0.0152	CbGpPWpGaD
Meloxicam—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	7.41e-05	0.0145	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—SERPINB8—psoriasis	7.34e-05	0.0144	CbGpPWpGaD
Meloxicam—PGD—tendon—psoriasis	7.32e-05	0.0655	CbGeAlD
Meloxicam—PTGS1—Biological oxidations—CYP2S1—psoriasis	6.72e-05	0.0132	CbGpPWpGaD
Meloxicam—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6.65e-05	0.0131	CbGpPWpGaD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	6.12e-05	0.012	CbGpPWpGaD
Meloxicam—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	6.07e-05	0.0119	CbGpPWpGaD
Meloxicam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	5.41e-05	0.0106	CbGpPWpGaD
Meloxicam—Vomiting—Mycophenolic acid—psoriasis	5.4e-05	0.000328	CcSEcCtD
Meloxicam—Discomfort—Betamethasone—psoriasis	5.37e-05	0.000327	CcSEcCtD
Meloxicam—Discomfort—Dexamethasone—psoriasis	5.37e-05	0.000327	CcSEcCtD
Meloxicam—Dyspepsia—Hydrocortisone—psoriasis	5.37e-05	0.000327	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—psoriasis	5.37e-05	0.000327	CcSEcCtD
Meloxicam—Rash—Mycophenolic acid—psoriasis	5.35e-05	0.000326	CcSEcCtD
Meloxicam—Dermatitis—Mycophenolic acid—psoriasis	5.35e-05	0.000325	CcSEcCtD
Meloxicam—Pain—Prednisolone—psoriasis	5.34e-05	0.000325	CcSEcCtD
Meloxicam—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	5.34e-05	0.0105	CbGpPWpGaD
Meloxicam—Hepatitis—Methotrexate—psoriasis	5.34e-05	0.000325	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—psoriasis	5.34e-05	0.000325	CcSEcCtD
Meloxicam—Urticaria—Mycophenolate mofetil—psoriasis	5.32e-05	0.000324	CcSEcCtD
Meloxicam—Headache—Mycophenolic acid—psoriasis	5.32e-05	0.000324	CcSEcCtD
Meloxicam—ABCC4—NRF2 pathway—TGFA—psoriasis	5.31e-05	0.0104	CbGpPWpGaD
Meloxicam—Decreased appetite—Hydrocortisone—psoriasis	5.3e-05	0.000323	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—psoriasis	5.3e-05	0.000323	CcSEcCtD
Meloxicam—Body temperature increased—Mycophenolate mofetil—psoriasis	5.29e-05	0.000322	CcSEcCtD
Meloxicam—Abdominal pain—Mycophenolate mofetil—psoriasis	5.29e-05	0.000322	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—psoriasis	5.27e-05	0.000321	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.27e-05	0.000321	CcSEcCtD
Meloxicam—Fatigue—Hydrocortisone—psoriasis	5.26e-05	0.00032	CcSEcCtD
Meloxicam—Vision blurred—Prednisone—psoriasis	5.24e-05	0.000319	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—psoriasis	5.23e-05	0.000319	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.23e-05	0.000319	CcSEcCtD
Meloxicam—Pain—Hydrocortisone—psoriasis	5.22e-05	0.000318	CcSEcCtD
Meloxicam—Anaphylactic shock—Betamethasone—psoriasis	5.21e-05	0.000317	CcSEcCtD
Meloxicam—Oedema—Dexamethasone—psoriasis	5.21e-05	0.000317	CcSEcCtD
Meloxicam—Anaphylactic shock—Dexamethasone—psoriasis	5.21e-05	0.000317	CcSEcCtD
Meloxicam—Oedema—Betamethasone—psoriasis	5.21e-05	0.000317	CcSEcCtD
Meloxicam—ABCC4—tendon—psoriasis	5.21e-05	0.0466	CbGeAlD
Meloxicam—Insomnia—Triamcinolone—psoriasis	5.2e-05	0.000316	CcSEcCtD
Meloxicam—Infection—Betamethasone—psoriasis	5.18e-05	0.000315	CcSEcCtD
Meloxicam—Infection—Dexamethasone—psoriasis	5.18e-05	0.000315	CcSEcCtD
Meloxicam—Ill-defined disorder—Prednisone—psoriasis	5.16e-05	0.000314	CcSEcCtD
Meloxicam—Paraesthesia—Triamcinolone—psoriasis	5.16e-05	0.000314	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisolone—psoriasis	5.15e-05	0.000313	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—psoriasis	5.15e-05	0.000313	CcSEcCtD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	5.14e-05	0.0101	CbGpPWpGaD
Meloxicam—Anaemia—Prednisone—psoriasis	5.14e-05	0.000313	CcSEcCtD
Meloxicam—Shock—Dexamethasone—psoriasis	5.13e-05	0.000312	CcSEcCtD
Meloxicam—Shock—Betamethasone—psoriasis	5.13e-05	0.000312	CcSEcCtD
Meloxicam—Dyspnoea—Triamcinolone—psoriasis	5.12e-05	0.000312	CcSEcCtD
Meloxicam—Nervous system disorder—Dexamethasone—psoriasis	5.11e-05	0.000311	CcSEcCtD
Meloxicam—Nervous system disorder—Betamethasone—psoriasis	5.11e-05	0.000311	CcSEcCtD
Meloxicam—Thrombocytopenia—Betamethasone—psoriasis	5.1e-05	0.000311	CcSEcCtD
Meloxicam—Thrombocytopenia—Dexamethasone—psoriasis	5.1e-05	0.000311	CcSEcCtD
Meloxicam—Tachycardia—Betamethasone—psoriasis	5.09e-05	0.00031	CcSEcCtD
Meloxicam—Tachycardia—Dexamethasone—psoriasis	5.09e-05	0.00031	CcSEcCtD
Meloxicam—Angioedema—Prednisone—psoriasis	5.08e-05	0.000309	CcSEcCtD
Meloxicam—Hypersensitivity—Cyclosporine—psoriasis	5.06e-05	0.000308	CcSEcCtD
Meloxicam—Dyspepsia—Triamcinolone—psoriasis	5.06e-05	0.000308	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—psoriasis	5.05e-05	0.000307	CcSEcCtD
Meloxicam—Nausea—Mycophenolic acid—psoriasis	5.04e-05	0.000307	CcSEcCtD
Meloxicam—Hyperhidrosis—Betamethasone—psoriasis	5.04e-05	0.000307	CcSEcCtD
Meloxicam—Hyperhidrosis—Dexamethasone—psoriasis	5.04e-05	0.000307	CcSEcCtD
Meloxicam—Feeling abnormal—Hydrocortisone—psoriasis	5.03e-05	0.000306	CcSEcCtD
Meloxicam—Malaise—Prednisone—psoriasis	5.02e-05	0.000305	CcSEcCtD
Meloxicam—Vertigo—Prednisone—psoriasis	5e-05	0.000304	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—psoriasis	4.99e-05	0.000304	CcSEcCtD
Meloxicam—Gastrointestinal pain—Hydrocortisone—psoriasis	4.99e-05	0.000304	CcSEcCtD
Meloxicam—Syncope—Prednisone—psoriasis	4.99e-05	0.000304	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—psoriasis	4.98e-05	0.000303	CcSEcCtD
Meloxicam—Urticaria—Prednisolone—psoriasis	4.96e-05	0.000302	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—psoriasis	4.96e-05	0.000302	CcSEcCtD
Meloxicam—Fatigue—Triamcinolone—psoriasis	4.95e-05	0.000301	CcSEcCtD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	4.95e-05	0.00971	CbGpPWpGaD
Meloxicam—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.93e-05	0.0003	CcSEcCtD
Meloxicam—Asthenia—Cyclosporine—psoriasis	4.93e-05	0.0003	CcSEcCtD
Meloxicam—Pain—Triamcinolone—psoriasis	4.91e-05	0.000299	CcSEcCtD
Meloxicam—Loss of consciousness—Prednisone—psoriasis	4.89e-05	0.000298	CcSEcCtD
Meloxicam—Hypotension—Betamethasone—psoriasis	4.87e-05	0.000296	CcSEcCtD
Meloxicam—Hypotension—Dexamethasone—psoriasis	4.87e-05	0.000296	CcSEcCtD
Meloxicam—Pruritus—Cyclosporine—psoriasis	4.86e-05	0.000296	CcSEcCtD
Meloxicam—Urticaria—Hydrocortisone—psoriasis	4.85e-05	0.000295	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—psoriasis	4.84e-05	0.000295	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—psoriasis	4.82e-05	0.000294	CcSEcCtD
Meloxicam—Body temperature increased—Hydrocortisone—psoriasis	4.82e-05	0.000294	CcSEcCtD
Meloxicam—Abdominal pain—Hydrocortisone—psoriasis	4.82e-05	0.000294	CcSEcCtD
Meloxicam—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	4.82e-05	0.00946	CbGpPWpGaD
Meloxicam—PGD—Metabolism—NDUFA5—psoriasis	4.82e-05	0.00946	CbGpPWpGaD
Meloxicam—Convulsion—Prednisone—psoriasis	4.82e-05	0.000293	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—psoriasis	4.81e-05	0.000293	CcSEcCtD
Meloxicam—Asthenia—Mycophenolate mofetil—psoriasis	4.8e-05	0.000292	CcSEcCtD
Meloxicam—Hypertension—Prednisone—psoriasis	4.8e-05	0.000292	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.75e-05	0.000289	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Betamethasone—psoriasis	4.75e-05	0.000289	CcSEcCtD
Meloxicam—Pruritus—Mycophenolate mofetil—psoriasis	4.74e-05	0.000288	CcSEcCtD
Meloxicam—Arthralgia—Prednisone—psoriasis	4.74e-05	0.000288	CcSEcCtD
Meloxicam—Myalgia—Prednisone—psoriasis	4.74e-05	0.000288	CcSEcCtD
Meloxicam—Feeling abnormal—Triamcinolone—psoriasis	4.73e-05	0.000288	CcSEcCtD
Meloxicam—Anxiety—Prednisone—psoriasis	4.72e-05	0.000287	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—psoriasis	4.72e-05	0.000287	CcSEcCtD
Meloxicam—Insomnia—Dexamethasone—psoriasis	4.71e-05	0.000287	CcSEcCtD
Meloxicam—Insomnia—Betamethasone—psoriasis	4.71e-05	0.000287	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.7e-05	0.000286	CcSEcCtD
Meloxicam—Diarrhoea—Cyclosporine—psoriasis	4.7e-05	0.000286	CcSEcCtD
Meloxicam—Paraesthesia—Betamethasone—psoriasis	4.68e-05	0.000285	CcSEcCtD
Meloxicam—Paraesthesia—Dexamethasone—psoriasis	4.68e-05	0.000285	CcSEcCtD
Meloxicam—Discomfort—Prednisone—psoriasis	4.68e-05	0.000285	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—psoriasis	4.68e-05	0.000285	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—psoriasis	4.65e-05	0.000283	CcSEcCtD
Meloxicam—Erythema—Methotrexate—psoriasis	4.65e-05	0.000283	CcSEcCtD
Meloxicam—Hypersensitivity—Prednisolone—psoriasis	4.6e-05	0.00028	CcSEcCtD
Meloxicam—Dyspepsia—Dexamethasone—psoriasis	4.59e-05	0.000279	CcSEcCtD
Meloxicam—Dyspepsia—Betamethasone—psoriasis	4.59e-05	0.000279	CcSEcCtD
Meloxicam—Diarrhoea—Mycophenolate mofetil—psoriasis	4.58e-05	0.000279	CcSEcCtD
Meloxicam—Urticaria—Triamcinolone—psoriasis	4.56e-05	0.000278	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—psoriasis	4.55e-05	0.000277	CcSEcCtD
Meloxicam—Body temperature increased—Triamcinolone—psoriasis	4.54e-05	0.000276	CcSEcCtD
Meloxicam—Dizziness—Cyclosporine—psoriasis	4.54e-05	0.000276	CcSEcCtD
Meloxicam—Oedema—Prednisone—psoriasis	4.54e-05	0.000276	CcSEcCtD
Meloxicam—Anaphylactic shock—Prednisone—psoriasis	4.54e-05	0.000276	CcSEcCtD
Meloxicam—Decreased appetite—Dexamethasone—psoriasis	4.53e-05	0.000276	CcSEcCtD
Meloxicam—Decreased appetite—Betamethasone—psoriasis	4.53e-05	0.000276	CcSEcCtD
Meloxicam—Infection—Prednisone—psoriasis	4.51e-05	0.000275	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Dexamethasone—psoriasis	4.5e-05	0.000274	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Betamethasone—psoriasis	4.5e-05	0.000274	CcSEcCtD
Meloxicam—Back pain—Methotrexate—psoriasis	4.5e-05	0.000274	CcSEcCtD
Meloxicam—Hypersensitivity—Hydrocortisone—psoriasis	4.49e-05	0.000274	CcSEcCtD
Meloxicam—Fatigue—Dexamethasone—psoriasis	4.49e-05	0.000274	CcSEcCtD
Meloxicam—Fatigue—Betamethasone—psoriasis	4.49e-05	0.000274	CcSEcCtD
Meloxicam—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	4.49e-05	0.00882	CbGpPWpGaD
Meloxicam—Shock—Prednisone—psoriasis	4.47e-05	0.000272	CcSEcCtD
Meloxicam—Pain—Betamethasone—psoriasis	4.46e-05	0.000271	CcSEcCtD
Meloxicam—Pain—Dexamethasone—psoriasis	4.46e-05	0.000271	CcSEcCtD
Meloxicam—Nervous system disorder—Prednisone—psoriasis	4.45e-05	0.000271	CcSEcCtD
Meloxicam—Tachycardia—Prednisone—psoriasis	4.43e-05	0.00027	CcSEcCtD
Meloxicam—Dizziness—Mycophenolate mofetil—psoriasis	4.43e-05	0.00027	CcSEcCtD
Meloxicam—Skin disorder—Prednisone—psoriasis	4.41e-05	0.000268	CcSEcCtD
Meloxicam—Hyperhidrosis—Prednisone—psoriasis	4.39e-05	0.000267	CcSEcCtD
Meloxicam—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	4.39e-05	0.00861	CbGpPWpGaD
Meloxicam—Vision blurred—Methotrexate—psoriasis	4.38e-05	0.000267	CcSEcCtD
Meloxicam—Asthenia—Hydrocortisone—psoriasis	4.38e-05	0.000266	CcSEcCtD
Meloxicam—Vomiting—Cyclosporine—psoriasis	4.36e-05	0.000266	CcSEcCtD
Meloxicam—CYP2C8—Biological oxidations—CYP2S1—psoriasis	4.34e-05	0.00852	CbGpPWpGaD
Meloxicam—Rash—Cyclosporine—psoriasis	4.33e-05	0.000263	CcSEcCtD
Meloxicam—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	4.33e-05	0.00849	CbGpPWpGaD
Meloxicam—Dermatitis—Cyclosporine—psoriasis	4.32e-05	0.000263	CcSEcCtD
Meloxicam—Pruritus—Hydrocortisone—psoriasis	4.32e-05	0.000263	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—psoriasis	4.31e-05	0.000263	CcSEcCtD
Meloxicam—Headache—Cyclosporine—psoriasis	4.3e-05	0.000262	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—psoriasis	4.3e-05	0.000262	CcSEcCtD
Meloxicam—Feeling abnormal—Dexamethasone—psoriasis	4.3e-05	0.000261	CcSEcCtD
Meloxicam—Feeling abnormal—Betamethasone—psoriasis	4.3e-05	0.000261	CcSEcCtD
Meloxicam—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	4.28e-05	0.0084	CbGpPWpGaD
Meloxicam—Gastrointestinal pain—Betamethasone—psoriasis	4.26e-05	0.000259	CcSEcCtD
Meloxicam—Gastrointestinal pain—Dexamethasone—psoriasis	4.26e-05	0.000259	CcSEcCtD
Meloxicam—Vomiting—Mycophenolate mofetil—psoriasis	4.26e-05	0.000259	CcSEcCtD
Meloxicam—Hypersensitivity—Triamcinolone—psoriasis	4.23e-05	0.000258	CcSEcCtD
Meloxicam—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	4.23e-05	0.0083	CbGpPWpGaD
Meloxicam—Rash—Mycophenolate mofetil—psoriasis	4.22e-05	0.000257	CcSEcCtD
Meloxicam—Dermatitis—Mycophenolate mofetil—psoriasis	4.22e-05	0.000257	CcSEcCtD
Meloxicam—Headache—Mycophenolate mofetil—psoriasis	4.2e-05	0.000255	CcSEcCtD
Meloxicam—Malaise—Methotrexate—psoriasis	4.19e-05	0.000255	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—psoriasis	4.18e-05	0.000254	CcSEcCtD
Meloxicam—Diarrhoea—Hydrocortisone—psoriasis	4.17e-05	0.000254	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—psoriasis	4.16e-05	0.000253	CcSEcCtD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	4.15e-05	0.00814	CbGpPWpGaD
Meloxicam—Urticaria—Betamethasone—psoriasis	4.14e-05	0.000252	CcSEcCtD
Meloxicam—Urticaria—Dexamethasone—psoriasis	4.14e-05	0.000252	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Prednisone—psoriasis	4.14e-05	0.000252	CcSEcCtD
Meloxicam—Dizziness—Prednisolone—psoriasis	4.13e-05	0.000251	CcSEcCtD
Meloxicam—Asthenia—Triamcinolone—psoriasis	4.12e-05	0.000251	CcSEcCtD
Meloxicam—Body temperature increased—Dexamethasone—psoriasis	4.12e-05	0.000251	CcSEcCtD
Meloxicam—Abdominal pain—Dexamethasone—psoriasis	4.12e-05	0.000251	CcSEcCtD
Meloxicam—Abdominal pain—Betamethasone—psoriasis	4.12e-05	0.000251	CcSEcCtD
Meloxicam—Body temperature increased—Betamethasone—psoriasis	4.12e-05	0.000251	CcSEcCtD
Meloxicam—Insomnia—Prednisone—psoriasis	4.11e-05	0.00025	CcSEcCtD
Meloxicam—PGD—Metabolism—CYP2S1—psoriasis	4.1e-05	0.00804	CbGpPWpGaD
Meloxicam—Nausea—Cyclosporine—psoriasis	4.08e-05	0.000248	CcSEcCtD
Meloxicam—Paraesthesia—Prednisone—psoriasis	4.08e-05	0.000248	CcSEcCtD
Meloxicam—Pruritus—Triamcinolone—psoriasis	4.06e-05	0.000247	CcSEcCtD
Meloxicam—Cough—Methotrexate—psoriasis	4.06e-05	0.000247	CcSEcCtD
Meloxicam—Dizziness—Hydrocortisone—psoriasis	4.03e-05	0.000246	CcSEcCtD
Meloxicam—PTGS1—skin of body—psoriasis	4.03e-05	0.036	CbGeAlD
Meloxicam—Convulsion—Methotrexate—psoriasis	4.03e-05	0.000245	CcSEcCtD
Meloxicam—Dyspepsia—Prednisone—psoriasis	4e-05	0.000243	CcSEcCtD
Meloxicam—Nausea—Mycophenolate mofetil—psoriasis	3.98e-05	0.000242	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—psoriasis	3.96e-05	0.000241	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—psoriasis	3.96e-05	0.000241	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	3.96e-05	0.00776	CbGpPWpGaD
Meloxicam—Decreased appetite—Prednisone—psoriasis	3.95e-05	0.00024	CcSEcCtD
Meloxicam—Rash—Prednisolone—psoriasis	3.94e-05	0.00024	CcSEcCtD
Meloxicam—Dermatitis—Prednisolone—psoriasis	3.93e-05	0.00024	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.93e-05	0.000239	CcSEcCtD
Meloxicam—PTGS2—S1P1 pathway—VEGFA—psoriasis	3.92e-05	0.00768	CbGpPWpGaD
Meloxicam—Fatigue—Prednisone—psoriasis	3.91e-05	0.000238	CcSEcCtD
Meloxicam—Headache—Prednisolone—psoriasis	3.91e-05	0.000238	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—psoriasis	3.91e-05	0.000238	CcSEcCtD
Meloxicam—Constipation—Prednisone—psoriasis	3.88e-05	0.000236	CcSEcCtD
Meloxicam—Vomiting—Hydrocortisone—psoriasis	3.88e-05	0.000236	CcSEcCtD
Meloxicam—PTGS2—skin of body—psoriasis	3.85e-05	0.0344	CbGeAlD
Meloxicam—Rash—Hydrocortisone—psoriasis	3.85e-05	0.000234	CcSEcCtD
Meloxicam—Dermatitis—Hydrocortisone—psoriasis	3.84e-05	0.000234	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—psoriasis	3.83e-05	0.000233	CcSEcCtD
Meloxicam—Headache—Hydrocortisone—psoriasis	3.82e-05	0.000233	CcSEcCtD
Meloxicam—Dizziness—Triamcinolone—psoriasis	3.8e-05	0.000231	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—psoriasis	3.79e-05	0.000231	CcSEcCtD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.77e-05	0.00739	CbGpPWpGaD
Meloxicam—Infection—Methotrexate—psoriasis	3.77e-05	0.000229	CcSEcCtD
Meloxicam—Feeling abnormal—Prednisone—psoriasis	3.74e-05	0.000228	CcSEcCtD
Meloxicam—Asthenia—Betamethasone—psoriasis	3.74e-05	0.000228	CcSEcCtD
Meloxicam—Asthenia—Dexamethasone—psoriasis	3.74e-05	0.000228	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—psoriasis	3.72e-05	0.000226	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—psoriasis	3.71e-05	0.000226	CcSEcCtD
Meloxicam—Gastrointestinal pain—Prednisone—psoriasis	3.71e-05	0.000226	CcSEcCtD
Meloxicam—Nausea—Prednisolone—psoriasis	3.71e-05	0.000226	CcSEcCtD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	3.7e-05	0.00725	CbGpPWpGaD
Meloxicam—Pruritus—Dexamethasone—psoriasis	3.69e-05	0.000224	CcSEcCtD
Meloxicam—Pruritus—Betamethasone—psoriasis	3.69e-05	0.000224	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—psoriasis	3.68e-05	0.000224	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—psoriasis	3.67e-05	0.000223	CcSEcCtD
Meloxicam—Vomiting—Triamcinolone—psoriasis	3.65e-05	0.000222	CcSEcCtD
Meloxicam—Nausea—Hydrocortisone—psoriasis	3.62e-05	0.000221	CcSEcCtD
Meloxicam—Rash—Triamcinolone—psoriasis	3.62e-05	0.00022	CcSEcCtD
Meloxicam—Dermatitis—Triamcinolone—psoriasis	3.62e-05	0.00022	CcSEcCtD
Meloxicam—Urticaria—Prednisone—psoriasis	3.61e-05	0.00022	CcSEcCtD
Meloxicam—Headache—Triamcinolone—psoriasis	3.6e-05	0.000219	CcSEcCtD
Meloxicam—Abdominal pain—Prednisone—psoriasis	3.59e-05	0.000218	CcSEcCtD
Meloxicam—Body temperature increased—Prednisone—psoriasis	3.59e-05	0.000218	CcSEcCtD
Meloxicam—Diarrhoea—Dexamethasone—psoriasis	3.57e-05	0.000217	CcSEcCtD
Meloxicam—Diarrhoea—Betamethasone—psoriasis	3.57e-05	0.000217	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—psoriasis	3.54e-05	0.000216	CcSEcCtD
Meloxicam—CYP2C9—Biological oxidations—CYP2S1—psoriasis	3.53e-05	0.00693	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	3.48e-05	0.00684	CbGpPWpGaD
Meloxicam—Musculoskeletal discomfort—Methotrexate—psoriasis	3.46e-05	0.00021	CcSEcCtD
Meloxicam—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	3.45e-05	0.00677	CbGpPWpGaD
Meloxicam—Dizziness—Betamethasone—psoriasis	3.45e-05	0.00021	CcSEcCtD
Meloxicam—Dizziness—Dexamethasone—psoriasis	3.45e-05	0.00021	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—psoriasis	3.43e-05	0.000209	CcSEcCtD
Meloxicam—Nausea—Triamcinolone—psoriasis	3.41e-05	0.000208	CcSEcCtD
Meloxicam—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	3.41e-05	0.00669	CbGpPWpGaD
Meloxicam—Paraesthesia—Methotrexate—psoriasis	3.41e-05	0.000207	CcSEcCtD
Meloxicam—ABCC4—Fluoropyrimidine Activity—TP53—psoriasis	3.4e-05	0.00667	CbGpPWpGaD
Meloxicam—Dyspnoea—Methotrexate—psoriasis	3.38e-05	0.000206	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—psoriasis	3.37e-05	0.000205	CcSEcCtD
Meloxicam—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	3.36e-05	0.00659	CbGpPWpGaD
Meloxicam—Hypersensitivity—Prednisone—psoriasis	3.34e-05	0.000204	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—psoriasis	3.34e-05	0.000203	CcSEcCtD
Meloxicam—Vomiting—Dexamethasone—psoriasis	3.31e-05	0.000202	CcSEcCtD
Meloxicam—Vomiting—Betamethasone—psoriasis	3.31e-05	0.000202	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—psoriasis	3.3e-05	0.000201	CcSEcCtD
Meloxicam—Rash—Dexamethasone—psoriasis	3.29e-05	0.0002	CcSEcCtD
Meloxicam—Rash—Betamethasone—psoriasis	3.29e-05	0.0002	CcSEcCtD
Meloxicam—Dermatitis—Dexamethasone—psoriasis	3.28e-05	0.0002	CcSEcCtD
Meloxicam—Dermatitis—Betamethasone—psoriasis	3.28e-05	0.0002	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—psoriasis	3.28e-05	0.000199	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—psoriasis	3.27e-05	0.000199	CcSEcCtD
Meloxicam—Headache—Dexamethasone—psoriasis	3.27e-05	0.000199	CcSEcCtD
Meloxicam—Headache—Betamethasone—psoriasis	3.27e-05	0.000199	CcSEcCtD
Meloxicam—Asthenia—Prednisone—psoriasis	3.26e-05	0.000198	CcSEcCtD
Meloxicam—Pain—Methotrexate—psoriasis	3.24e-05	0.000197	CcSEcCtD
Meloxicam—Pruritus—Prednisone—psoriasis	3.21e-05	0.000195	CcSEcCtD
Meloxicam—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	3.2e-05	0.00627	CbGpPWpGaD
Meloxicam—Feeling abnormal—Methotrexate—psoriasis	3.13e-05	0.00019	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.12e-05	0.00611	CbGpPWpGaD
Meloxicam—Diarrhoea—Prednisone—psoriasis	3.11e-05	0.000189	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—psoriasis	3.1e-05	0.000189	CcSEcCtD
Meloxicam—Nausea—Betamethasone—psoriasis	3.1e-05	0.000188	CcSEcCtD
Meloxicam—Nausea—Dexamethasone—psoriasis	3.1e-05	0.000188	CcSEcCtD
Meloxicam—PTGS1—tendon—psoriasis	3.07e-05	0.0274	CbGeAlD
Meloxicam—Urticaria—Methotrexate—psoriasis	3.01e-05	0.000183	CcSEcCtD
Meloxicam—Dizziness—Prednisone—psoriasis	3e-05	0.000183	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—psoriasis	3e-05	0.000183	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—psoriasis	3e-05	0.000183	CcSEcCtD
Meloxicam—PTGS2—tendon—psoriasis	2.93e-05	0.0262	CbGeAlD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	2.91e-05	0.00572	CbGpPWpGaD
Meloxicam—Vomiting—Prednisone—psoriasis	2.89e-05	0.000176	CcSEcCtD
Meloxicam—Rash—Prednisone—psoriasis	2.86e-05	0.000174	CcSEcCtD
Meloxicam—Dermatitis—Prednisone—psoriasis	2.86e-05	0.000174	CcSEcCtD
Meloxicam—Headache—Prednisone—psoriasis	2.84e-05	0.000173	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—psoriasis	2.79e-05	0.00017	CcSEcCtD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	2.75e-05	0.00539	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	2.74e-05	0.00538	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	2.74e-05	0.00538	CbGpPWpGaD
Meloxicam—Asthenia—Methotrexate—psoriasis	2.72e-05	0.000166	CcSEcCtD
Meloxicam—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	2.71e-05	0.00531	CbGpPWpGaD
Meloxicam—Nausea—Prednisone—psoriasis	2.7e-05	0.000164	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—psoriasis	2.68e-05	0.000163	CcSEcCtD
Meloxicam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.63e-05	0.00516	CbGpPWpGaD
Meloxicam—Diarrhoea—Methotrexate—psoriasis	2.6e-05	0.000158	CcSEcCtD
Meloxicam—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	2.52e-05	0.00494	CbGpPWpGaD
Meloxicam—Dizziness—Methotrexate—psoriasis	2.51e-05	0.000153	CcSEcCtD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.49e-05	0.00488	CbGpPWpGaD
Meloxicam—Vomiting—Methotrexate—psoriasis	2.41e-05	0.000147	CcSEcCtD
Meloxicam—Rash—Methotrexate—psoriasis	2.39e-05	0.000146	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	2.39e-05	0.00469	CbGpPWpGaD
Meloxicam—Dermatitis—Methotrexate—psoriasis	2.39e-05	0.000145	CcSEcCtD
Meloxicam—Headache—Methotrexate—psoriasis	2.38e-05	0.000145	CcSEcCtD
Meloxicam—CYP3A4—Biological oxidations—CYP2S1—psoriasis	2.33e-05	0.00457	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	2.3e-05	0.00451	CbGpPWpGaD
Meloxicam—Nausea—Methotrexate—psoriasis	2.25e-05	0.000137	CcSEcCtD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	2.22e-05	0.00436	CbGpPWpGaD
Meloxicam—ABCC4—Platelet degranulation—VEGFA—psoriasis	2.22e-05	0.00435	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	2.18e-05	0.00427	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—ITGAL—psoriasis	2.13e-05	0.00418	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.13e-05	0.00417	CbGpPWpGaD
Meloxicam—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.11e-05	0.00414	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	2.07e-05	0.00406	CbGpPWpGaD
Meloxicam—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.01e-05	0.00394	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CARM1—psoriasis	2e-05	0.00393	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	2e-05	0.00392	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL4—psoriasis	1.99e-05	0.0039	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.93e-05	0.00379	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	1.92e-05	0.00376	CbGpPWpGaD
Meloxicam—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	1.82e-05	0.00356	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	1.78e-05	0.0035	CbGpPWpGaD
Meloxicam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.73e-05	0.0034	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	1.7e-05	0.00334	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—LEP—psoriasis	1.68e-05	0.0033	CbGpPWpGaD
Meloxicam—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.65e-05	0.00325	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	1.59e-05	0.00313	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	1.58e-05	0.0031	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—NOS2—psoriasis	1.57e-05	0.00308	CbGpPWpGaD
Meloxicam—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	1.55e-05	0.00304	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—CD4—psoriasis	1.53e-05	0.00299	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	1.52e-05	0.00298	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NDUFA5—psoriasis	1.35e-05	0.00265	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.27e-05	0.00249	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	1.27e-05	0.00248	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.26e-05	0.00247	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	1.24e-05	0.00243	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CAT—psoriasis	1.23e-05	0.00242	CbGpPWpGaD
Meloxicam—PGD—Disease—HLA-A—psoriasis	1.22e-05	0.0024	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IFNG—psoriasis	1.2e-05	0.00236	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CYP2S1—psoriasis	1.15e-05	0.00226	CbGpPWpGaD
Meloxicam—PGD—Disease—APOE—psoriasis	1.14e-05	0.00224	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	1.12e-05	0.00219	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NDUFA5—psoriasis	1.07e-05	0.00211	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.07e-05	0.00209	CbGpPWpGaD
Meloxicam—PGD—Disease—NOS2—psoriasis	1.06e-05	0.00209	CbGpPWpGaD
Meloxicam—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1e-05	0.00196	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1e-05	0.00196	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	9.85e-06	0.00193	CbGpPWpGaD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.83e-06	0.00193	CbGpPWpGaD
Meloxicam—PGD—Metabolism—APOE—psoriasis	9.56e-06	0.00188	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP2S1—psoriasis	9.12e-06	0.00179	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—NOS2—psoriasis	8.75e-06	0.00172	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NDUFA5—psoriasis	8.73e-06	0.00171	CbGpPWpGaD
Meloxicam—PGD—Disease—TYK2—psoriasis	8.72e-06	0.00171	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PPARG—psoriasis	8.33e-06	0.00163	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.14e-06	0.0016	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	7.95e-06	0.00156	CbGpPWpGaD
Meloxicam—PGD—Disease—CD4—psoriasis	7.88e-06	0.00155	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TNF—psoriasis	7.79e-06	0.00153	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP2S1—psoriasis	7.42e-06	0.00146	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NDUFA5—psoriasis	7.11e-06	0.00139	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.07e-06	0.00139	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TP53—psoriasis	6.87e-06	0.00135	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.81e-06	0.00134	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.63e-06	0.0013	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL6—psoriasis	6.28e-06	0.00123	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.18e-06	0.00121	CbGpPWpGaD
Meloxicam—PGD—Disease—STAT3—psoriasis	6.1e-06	0.0012	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP2S1—psoriasis	6.04e-06	0.00119	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.02e-06	0.00118	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CARM1—psoriasis	5.61e-06	0.0011	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.3e-06	0.00104	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.25e-06	0.00103	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—VEGFA—psoriasis	5.07e-06	0.000994	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.78e-06	0.000938	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NDUFA5—psoriasis	4.69e-06	0.00092	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.67e-06	0.000916	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CARM1—psoriasis	4.46e-06	0.000874	CbGpPWpGaD
Meloxicam—PGD—Disease—IL6—psoriasis	4.26e-06	0.000836	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.17e-06	0.000817	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP2S1—psoriasis	3.99e-06	0.000782	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.89e-06	0.000763	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TP53—psoriasis	3.83e-06	0.000751	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CARM1—psoriasis	3.63e-06	0.000711	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CAT—psoriasis	3.45e-06	0.000677	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.39e-06	0.000665	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.17e-06	0.000621	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CARM1—psoriasis	2.95e-06	0.000579	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.76e-06	0.000541	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CAT—psoriasis	2.74e-06	0.000538	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HLA-A—psoriasis	2.72e-06	0.000534	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—APOE—psoriasis	2.68e-06	0.000526	CbGpPWpGaD
Meloxicam—PTGS2—Disease—APOE—psoriasis	2.54e-06	0.000499	CbGpPWpGaD
Meloxicam—PTGS2—Disease—NOS2—psoriasis	2.37e-06	0.000465	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PPARG—psoriasis	2.34e-06	0.000458	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CAT—psoriasis	2.23e-06	0.000438	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—APOE—psoriasis	2.13e-06	0.000418	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CARM1—psoriasis	1.95e-06	0.000382	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TYK2—psoriasis	1.94e-06	0.000381	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PPARG—psoriasis	1.85e-06	0.000364	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CAT—psoriasis	1.82e-06	0.000356	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CD4—psoriasis	1.76e-06	0.000344	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—APOE—psoriasis	1.73e-06	0.00034	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PPARG—psoriasis	1.51e-06	0.000296	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—APOE—psoriasis	1.41e-06	0.000277	CbGpPWpGaD
Meloxicam—PTGS2—Disease—STAT3—psoriasis	1.36e-06	0.000267	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PPARG—psoriasis	1.23e-06	0.000241	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CAT—psoriasis	1.2e-06	0.000235	CbGpPWpGaD
Meloxicam—PTGS2—Disease—IL6—psoriasis	9.49e-07	0.000186	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—APOE—psoriasis	9.3e-07	0.000182	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PPARG—psoriasis	8.1e-07	0.000159	CbGpPWpGaD
